Vertex Pharmaceuticals (NASDAQ:VRTX) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $480.00 target price on the pharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on VRTX. Truist Financial reduced their price objective on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Finally, BMO Capital Markets dropped their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Ten investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $505.29.

Vertex Pharmaceuticals Stock Down 3.1 %

Vertex Pharmaceuticals stock opened at $455.22 on Tuesday. The company has a market capitalization of $117.23 billion, a PE ratio of -228.75, a PEG ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The firm’s fifty day moving average is $435.95 and its 200 day moving average is $462.13. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. As a group, sell-side analysts predict that Vertex Pharmaceuticals will post -1.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Northwest Investment Counselors LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $27,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $30,000. Finally, Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at about $33,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.